SE Health

sehc.com

SE Health (Saint Elizabeth Health Care) is a social enterprise applying knowledge, vision and drive to forever impact how people live and age at home, today and into the future. With Canadian roots and 110 years of expertise, the not-for-profit organization brings quality excellence and innovation to home care, seniors lifestyle and family caregiving. Through its team of 9,000 Leaders of Impact, SE Health delivers 20,000 care exchanges daily, totaling 50 million in the last decade alone.

Related News

BIOGEN TO PRESENT AT THE 25TH ANNUAL CREDIT SUISSE HEALTHCARE CONFERENCE

Biogen | October 27, 2016

news image

Biogen Inc. (NASDAQ: BIIB) announced today that it will present at the 25th Annual Credit Suisse Healthcare Conference. The webcast will be live on Monday, November 7, 2016 at 9:00a.m. MT, 11:00a.m. ET. To access the live webcast, please visit Biogen’s Investors section at www.biogen.com/investors. An archived version of the webcast will be available for 14 days following the presentation....

Read More

VERTEX TO PRESENT AT THE CREDIT SUISSE HEALTHCARE CONFERENCE ON NOVEMBER 8

Vertex Pharmaceuticals | November 02, 2016

news image

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Credit Suisse Healthcare Conference on Tuesday, November 8th at 3:30 p.m. ET .Management's remarks will be available live through Vertex's website at www.vrtx.com in the "Investors" section under the "Events and Presentations" page. A replay of the conference webcast will be archived on the company's website....

Read More

A FUTURE GENE THERAPY COULD BE DELIVERED IN TINY ‘NANOCONTAINERS’

Labiotech.eu | January 28, 2020

news image

A Swiss research group has developed tiny plastic particles that could carry gene therapies to the center of the cell with less risk of getting attacked by the immune system than conventional gene therapies. The majority of gene therapies in use today are delivered to the DNA of target cells using viral vectors. While efficient at their job, viral vectors can risk triggering the immune system to destroy them. This can lead to the therapy becoming ineffective....

Read More

J&J JUMPING IN ON CORONAVIRUS VAX WORK AS DISEASE CONTINUES ITS SPREAD

FierceBiotech | January 27, 2020

news image

Johnson & Johnson is joining the growing ranks of biopharmas, including the likes of Moderna and Gilead Sciences, in trying to create a speedy vaccine for the coronavirus out of China. Over the weekend, we learned of a wider range and more deaths as the new virus, which appears to have come out of Wuhan, China, is doing what these diseases do best: spread. The causes of death have so far been reported as pneumonia, with other reports suggesting most of these have come from those with underly...

Read More
news image

BIOGEN TO PRESENT AT THE 25TH ANNUAL CREDIT SUISSE HEALTHCARE CONFERENCE

Biogen | October 27, 2016

Biogen Inc. (NASDAQ: BIIB) announced today that it will present at the 25th Annual Credit Suisse Healthcare Conference. The webcast will be live on Monday, November 7, 2016 at 9:00a.m. MT, 11:00a.m. ET. To access the live webcast, please visit Biogen’s Investors section at www.biogen.com/investors. An archived version of the webcast will be available for 14 days following the presentation....

Read More
news image

VERTEX TO PRESENT AT THE CREDIT SUISSE HEALTHCARE CONFERENCE ON NOVEMBER 8

Vertex Pharmaceuticals | November 02, 2016

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Credit Suisse Healthcare Conference on Tuesday, November 8th at 3:30 p.m. ET .Management's remarks will be available live through Vertex's website at www.vrtx.com in the "Investors" section under the "Events and Presentations" page. A replay of the conference webcast will be archived on the company's website....

Read More
news image

A FUTURE GENE THERAPY COULD BE DELIVERED IN TINY ‘NANOCONTAINERS’

Labiotech.eu | January 28, 2020

A Swiss research group has developed tiny plastic particles that could carry gene therapies to the center of the cell with less risk of getting attacked by the immune system than conventional gene therapies. The majority of gene therapies in use today are delivered to the DNA of target cells using viral vectors. While efficient at their job, viral vectors can risk triggering the immune system to destroy them. This can lead to the therapy becoming ineffective....

Read More
news image

J&J JUMPING IN ON CORONAVIRUS VAX WORK AS DISEASE CONTINUES ITS SPREAD

FierceBiotech | January 27, 2020

Johnson & Johnson is joining the growing ranks of biopharmas, including the likes of Moderna and Gilead Sciences, in trying to create a speedy vaccine for the coronavirus out of China. Over the weekend, we learned of a wider range and more deaths as the new virus, which appears to have come out of Wuhan, China, is doing what these diseases do best: spread. The causes of death have so far been reported as pneumonia, with other reports suggesting most of these have come from those with underly...

Read More